6-bromo-3-methylbenzo[b]thiophene | 19075-36-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 6-bromo-3-methylbenzo[b]thiophene
• 英文别名: 6-bromo-3-methyl-1-benzothiophene
• CAS: 19075-36-6
• 化学式: C₉H₇BrS
• 分子量: 227.125
• InChiKey: VJWZLWALLQZYKL-UHFFFAOYSA-N

物化性质

• 沸点：
  138-139 °C(Press: 4 Torr)
• 密度：
  1.561±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-bromo-3-methylbenzo[b]thiophene 在 silica gel 、 钯 、 polyethylenimine 1,1-二溴乙烷 、 氢气 、 对甲苯磺酸 、 magnesium 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 甲苯 为溶剂， 生成 1-(2-methyl-1H-indol-4-yloxy)-3-[2-methyl-4-(3-methyl-benzo[b]thiophen-6-yl)-piperidin-1-yl]-propan-2-ol
  参考文献：
  名称：

  Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 4

  摘要：

  A series of 1-(1H-indol-4-yloxy)-3-(4-arylpiperidinyl)propan-2-ols possessing potent dual 5-HT1A receptor antagonism and serotonin reuptake inhibition was discovered. The fused aryl ring moiety contributed to the robust dual activities irrespective of the regiochemistry associated with its connectivity to the piperidine central ring. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.088
• 作为产物：
  描述：

  (3-bromophenyl)(2,2-dimethoxypropyl)sulfane 在 PPA 作用下， 以 氯苯 为溶剂， 反应 2.08h， 生成 6-bromo-3-methylbenzo[b]thiophene 、 4-bromo-3-methylbenzo[b]thiophene
  参考文献：
  名称：

  [EN] THIAZOLIDINONE COMPOUNDS, AND METHODS OF MAKING AND USING SAME
  [FR] COMPOSÉS DE THIAZOLIDINONE ET PROCÉDÉS DE PRÉPARATION ET D'UTILISATION DE CEUX-CI

  摘要：

  本发明提供了噻唑烷二酮化合物及其制备和使用方法。这类化合物可用于治疗炎症或免疫介导的疾病。本发明可用于治疗呼吸系统或眼部疾病、治疗关节炎，或可用于治疗癌症，如前列腺癌或乳腺癌，或多发性骨髓瘤。

  公开号：

  WO2009026345A1

文献信息

• [EN] SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS<br/>[FR] COMPOSÉS SPIRO-OXADIAZOLINE EN TANT QU'AGONISTES DES RÉCEPTEURS DE L'ACÉTYLCHOLINE Α-7 NICOTINIQUE
  申请人：FORUM PHARMACEUTICALS INC

  公开号：WO2015066371A1

  公开（公告）日：2015-05-07

  The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

  本发明涉及新型螺环-噁二唑啉化合物，适用作a7-nAChR的激动剂或部分激动剂，以及这些化合物和组合物的制备方法、药物组合物，以及在维持、治疗和/或改善认知功能的方法中使用这些化合物和组合物。具体而言，涉及向需要的患者（例如患有认知缺陷和/或希望增强认知功能的患者）施用螺环-噁二唑啉cx7-nAChR激动剂或部分激动剂的方法，以使其获益。
• Benzo-fused thromboxane synthetase inhibitors
  申请人：Pfizer Inc.

  公开号：US04496572A1

  公开（公告）日：1985-01-29

  A novel series of carboxy-substituted naphthalenes and carboxy-substituted benzo-fused heterocycles, such as carboxy-substituted derivatives of indole, benzofuran and benzothiophene, has been prepared, including their pharmaceutically acceptable salts. These particular compounds are useful in therapy for the treatment of thrombosis, ischaemic heart disease, stroke, transient ischaemic attack, migraine, peripheral vascular disease, the vascular complications of diabetes and endotoxic shock. Preferred member compounds include 2-(1-imidazolylmethyl)-3-methylbenzo[b]thiophene-5-carboxylic acid and 3-methyl-2-(3-pyridylmethyl)benzo[b]thiophene-5-carboxylic acid, respectively. Methods for preparing these compounds from known starting materials are provided.

  一系列新型的羧基取代萘衍生物和羧基取代的苯并杂环化合物已被制备，包括吲哚、苯并呋喃和苯并噻吩的羧基取代衍生物，以及它们的药用可接受盐。这些特定化合物在治疗血栓形成、缺血性心脏病、中风、短暂性脑缺血发作、偏头痛、外周血管疾病、糖尿病的血管并发症和内毒素性休克方面具有用途。优选的成员化合物包括2-(1-咪唑基甲基)-3-甲基苯并[b]噻吩-5-羧酸和3-甲基-2-(3-吡啶甲基)苯并[b]噻吩-5-羧酸。提供了从已知起始材料制备这些化合物的方法。
• Pharmaceutical compounds
  申请人：——

  公开号：US20040122001A1

  公开（公告）日：2004-06-24

  This invention relates to compounds of formula (I) where R 1 to R 12 , —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals. 1

  这项发明涉及到式(I)的化合物，其中R1至R12，—W—V—，—X—Y—，m和n的值如权利要求1中定义的，它们的制备和用作药物。
• [EN] 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS<br/>[FR] INHIBITEURS DE 17?-HYDROXYLASE/C17,20-LYASE
  申请人：NOVARTIS AG

  公开号：WO2012149413A1

  公开（公告）日：2012-11-01

  The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C17,20-lyase inhibitors.

  本发明提供了Formula (I)的化合物，或其药用可接受的盐，其中R1、R2、R3、R4、R5和R6如本文所定义。本发明的化合物被发现可用作17α-羟化酶/C17,20-裂解酶抑制剂。
• Halogeno-substituted 2- and 3-methylbenzo[b]thiophenes: Use of1H NMR spectral analysis and1H{1H} nuclear Overhauser effect for locating the halogen substituent
  作者：Ma. Rosa Cuberes、Marcial Moreno-Mañas、Francisco Sánchez-Ferrandom

  DOI：10.1002/mrc.1260231006

  日期：1985.10

  halogenomethyl)‐benzo [b]thiophenes, including 17 new compounds, were prepared. The constitution of 14 of these was confirmed by full analysis (LAOCOON) of their 80 MHz1HNMR spectra and by 1H1H} NOE measurements. In this way a by‐product from the preparation of 4‐ and 6‐bromo‐3‐bromomethylbenzo[b]thiophenes was shown conclusively to be 5‐bromo‐3‐bromomethylbenzo[b]thiophene. The 3‐substituted benzo[b]thiophenes showed

  制备了 37 个卤代 2- 和 3-甲基-（或卤甲基）-苯并 [b] 噻吩，包括 17 个新化合物。通过对它们的 80 MHz 1 HNMR 光谱的全面分析 (LAOCOON) 和 1H1H} NOE 测量，证实了其中 14 种的构成。通过这种方式，4-和6-溴-3-溴甲基苯并[b]噻吩的制备副产物最终显示为5-溴-3-溴甲基苯并[b]噻吩。当照射 3-甲基或卤代甲基取代基时，3-取代的苯并[b]噻吩在 H-4 处显示出比在 H-2 处更大的 NOE 增强因子。